PVLA · Palvella Therapeutics, Inc.
$125.10
-1.02% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-15.7
Dividend yield
0.0%
Beta
—
Avg volume
0M
Employees
0K
Daily Change %
-1.02%
5 Days Change
1.74%
10 Days Change
2.06%
30 Days Change
-14.36%
60 Days Change
-15.61%
Month to Day Change
-5.75%
Year to Day Change
19.52%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PVLA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-12 | HC Wainwright & Co. | Maintains | Buy | $270 → $246 |
| 2026-09-21 | Chardan Capital | Maintains | Buy | $240 |
| 2026-05-21 | Stephens & Co. | Reiterates | Overweight | $220 |
| 2026-05-21 | Chardan Capital | Maintains | Buy | $240 |
| 2026-05-12 | Stephens & Co. | Initiates | Overweight | $0.00 → $220 |
| 2026-03-31 | Chardan Capital | Maintains | Buy | $210 → $240 |
| 2026-03-24 | HC Wainwright & Co. | Maintains | Buy | $255 → $270 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 40 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 12.2% below the 50-day MA ($142.43).
- bearish: Price vs 200-day MA: Trading 0.6% below the 200-day MA ($125.90).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.10) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($70.43) and high ($158.13).
PVLA Price Chart
Loading chart for PVLA…
Fundamentals
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.